LOS ANGELES, Aug. 29 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. , is the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families in all 50 states and internationally. Matthew Schissler, CEO, is featured in an exclusive interview with Jason Buchen posted at http://www.EquityGroups.com .
The link to the interview is at http://equitygroups.com/audioint/cbai/cbai24aug.wmv .
In the interview, Mr. Schissler says investors should be increasingly interested in the stem cell sector because many more afflictions will be treated, and cured, by stem cells within the next two to five years. “We are the fastest growing stem cell company that we know about, and are highly undervalued,” the CEO of Cord Blood America said. “We are positioning our Company to be in control of the inventory, which is crucial to significant corporate growth.”
About Cord Blood America
Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. , visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as “anticipate,” “believe,” “expect,” “future,” “intend,” “plan,” and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company’s performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company’s public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company’s past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
Cord Blood America, Inc.
CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,pknopick@eandecommunications.com, for Cord Blood America, Inc.
